Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a phone app nudge people toward exercise and slow Parkinson's?

NCT ID NCT06193252

Prevention Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial tests whether a smartphone app can help people with REM sleep behavior disorder, a condition that often precedes Parkinson's, become more physically active over two years. Participants receive personalized activity goals through the app and track their steps and exercise intensity with a smartwatch. The study measures how well people stick with the program and looks for early signs of Parkinson's using digital, blood, and brain imaging markers. The goal is to see if boosting daily activity is a feasible way to potentially slow the disease's progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A motivational smartphone app that encourages increased physical activity
What this could lead to
If the app successfully boosts daily activity, it could point toward a way to slow or delay the onset of Parkinson's disease in people at early risk.
What could go wrong
The trial is early and small, and it focuses on feasibility rather than proven health outcomes. Participants may not stick with the app, and increased activity may not change the course of the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * previously diagnosed with iRBD meeting the following criteria according to the International Classification of Sleep Disorders (ICSD-3) * able to understand the Dutch language * being able to walk independently inside the home without the use of a walking aid * Not in a high physical activity range during the 4-week eligibility and baseline period * in possession of a suitable smartphone compatible with the Slow-SPEED app, the Fitbit app and the Roche PD Research Mobile application. Exclusion Criteria: * clinically diagnosed or self-reported diagnosis neurodegenerative disease; * self-reported weekly falls in the previous 3 months; * dexterity problems or cognitive impairments hampering smartphone use; * if they do not wish to be informed about an increased risk of developing diseases associated with iRBD * if individual is not community-dwelling Exclusion criteria for MRI only: * history of epilepsy, structural brain abnormalities (i.e. stroke, traumatic defects, large arachnoid cysts) or brain surgery * claustrophobia * implanted electrical devices (i.e. pacemaker, deep-brain stimulator (DBS), neurostimulator) * metal implants (such as prosthetics, ossicle prosthesis, metal plates or other non-removable metal part) or metal splinters * pregnancy * fear for incidental finding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Basal ganglia diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal ganglia disorder brain disorder central nervous system disorder Motor Activity nervous system disorder neurodegenerative disease Parkinson disease parkinsonian disorder Prodromal Symptoms REM sleep behavior disorder synucleinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Basal ganglia diseases Brain diseases Central nervous system diseases Cerebral disorder Nervous system diseases Neurodegenerative diseases Parkinson disease Parkinsonian disorders Prodromal stage Rem sleep behavior disorder Synucleinopathies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Radboud University Medical Center

    RECRUITING

    Nijmegen, Gelderland, 6525 GA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.